Início › Câncer do Trato Biliar › Ohio
Ensaios clínicos de Câncer do Trato Biliar em Ohio
10 estudos para Câncer do Trato Biliar estão buscando participantes em locais em Ohio.
Cidades em Ohio
Texto oficial do estudo (Inglês)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06760819A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- University Hospitals Cleveland Medical Center Seidman Cancer Center (Site 111), Cleveland
- James Cancer Hospital and Solove Research Institute (Site 119), Columbus
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07265674Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
RecrutandoFase 2
Idades de 18 a 130 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05489211Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
RecrutandoFase 2
Idades 19 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07146646A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Cleveland Clinic Taussig Cancer Institute, Cleveland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Cleveland
- Research Site, Columbus
RecrutandoFase 3
Idades de 18 a 99 · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT05592626D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
- University Hospital Cleveland Medical Center, Cleveland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT06622057A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nationwide Children's Hospital, Colombus
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
RecrutandoFase 2
Idades 8 e acima · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT05503797A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de dez. de 2025 · NCT06943521Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.